DRKS00006745已完成不适用
Prevalence of BRCA in Patients with primary platinum sensitive recurrent ovarian cancer
AGO Research GmbH, AGO Study Group0 个研究点目标入组 530 人开始时间: 2015年5月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 530
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- Female
入选标准
- •1. Female ovarian cancer patients aged >= 18 years.
- •2. Women with first diagnosis of epithelial ovarian cancer OR women diagnosed with platinum-sensitive recurrent ovarian cancer (i.e., women who have received an initial course of platinum-based chemotherapy and with no evidence of disease progression for at least 6 months after the last administration of a platinum-based regimen for initial treatment).
- •3. Multiple platinum based prior therapies are allowed.
排除标准
- •1. Non-epithelial ovarian malignancy.
- •2. Platinum resistant or refractory disease.
- •3. Paraffin embedded tumor samples not available.
研究者
相似试验
已完成
不适用
Prevalence of BRCA in Patients With Ovarian CancerBRCA StatusOvarian CancerNCT02222883AGO Research GmbH530
已完成
不适用
BRCA mutation in patients with ovarian cancer in KoreaNeoplasmsKCT0005463The Catholic University of Korea108
已完成
不适用
Prevalence of positive evolutive PCR in patients with COVID 19 treated with rectal ozone therapy: observational study prospective cohort.COVID-19SARS-CoV2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsNidovirales InfectionsBetacoronavirusDisease PreventionRPCEC00000341ational Center for Scientific Research (CNIC)200
已完成
不适用
Can a peer support program for women with an altered cancer gene reduce distress?Psychosocial effects of testing positive for a mutation of the BRCA1/2 geneCancer - Ovarian and primary peritonealMental Health - AnxietyCancer - BreastACTRN12608000343303The Cancer Council Victoria337
尚未招募
不适用
BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer OvaryOvarian CancerNCT06304922Assiut University45